alpramil 20 mg/200 mg tablety pre psov s hmotnosťou najmenej 8 kg
alfasan nederland b.v., holandsko - tbl.
alpramil 4 mg/10 mg filmom obalené tablety pre mačky s hmotnosťou najmenej 0,5 kg
alfasan nederland b.v., holandsko - tbl.
alpramil 5 mg/50 mg tablety pre psov s hmotnosťou najmenej 0,5 kg
alfasan nederland b.v., holandsko - tbl.
metaxx 5 mg/ml injekčný roztok pre hovädzí dobytok, ošípané, psy a mačky.
alfasan nederland b.v., holandsko - inj.
xylexx 20 mg/ml injekčný roztok pre hovädzí dobytok, kone, psy a mačky
alfasan nederland b.v., holandsko - inj.
metaxx 15 mg/ml perorálna suspenzia pre kone
alfasan nederland b.v., holandsko - susp.
metaxx 20 mg/ml injekčný roztok pre hovädzí dobytok, ošípané a kone
alfasan nederland b.v., holandsko - inj.
alkeran inj
aspen pharma trading limited, Írsko - melfalán - 44 - cytostatica
melphalan zentiva 50 mg prášok a rozpúšťadlo na injekčný/infúzny roztok
zentiva k.s., Česká republika - melfalán - 44 - cytostatica
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastické činidlá - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.